Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FUJRH
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,893
Award facts
- Contract value 100% obligated
- $1,892.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $1,892.90 by the Defense Logistics Agency on August 14, 2025, for the supply of Nucala 100 mg/mL auto-injector. This firm fixed-price delivery order, with an ultimate completion date of August 15, 2025, represents no set-aside designation and will be performed at the vendor's Park Ridge, Illinois location. The award is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to procure a comprehensive range of pharmaceutical items to support military health facilities worldwide.
Nucala (mepolizumab) is a biologic medication used in the treatment of eosinophil-driven conditions, and this delivery order fulfills a specific procurement need within the Defense Logistics Agency's broader pharmaceutical supply strategy. DMS Pharmaceutical Group has established itself as a critical supplier in the federal pharmaceutical supply chain, consistently securing contracts to distribute branded and generic prescription drugs, biologics, vaccines, and specialty medical consumables to Department of Defense healthcare sites. The company's robust portfolio of federal contract awards demonstrates its capability to reliably deliver specialized pharmaceutical products to military and federal healthcare facilities nationwide.
Quick answers
Who was awarded contract SPE2DB25FUJRH?
SPE2DB25FUJRH was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 14, 2025.
How much is contract SPE2DB25FUJRH worth?
The government has obligated $1,893 on SPE2DB25FUJRH.
Is contract SPE2DB25FUJRH an order under another contract?
Yes. SPE2DB25FUJRH is a delivery order under SPE2DB25D9365, an indefinite delivery contract.
Was contract SPE2DB25FUJRH competed?
The extent of competition for SPE2DB25FUJRH was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award